Sandra Hanington - Extendicare Independent Director
| EXE Stock | CAD 13.09 0.05 0.38% |
Director
Ms. Sandra Lynn Hanington is Independent Director of Extendicare Inc. Ms. Hanington is a corporate director and advisor, and most recently was the President and CEO of the Royal Canadian Mint . Prior to that, Ms. Hanington had deep experience in the financial services sector, and from 1999 to 2011 she held a number of progressively senior executive roles with BMO Financial Group in North America, including as Executive Vice President and a member of the Management Committee. Prior to joining BMO Financial Group, Ms. Hanington worked for Manulife FinancialNorth American Life Assurance, Royal Trustco Ltd. and Suncor Inc.Sunoco Group. Ms. Hanington is the cofounder and a director of Jack.org, promoting mental health and wellness for youth in Canada, since 2010. Ms. Hanington was named by the Womens Executive Network as one of Canadas Top 100 Most Powerful Women three times in a row, from 2007 to 2009, and was inducted into the WXN Hall of Fame in 2010 since 2014.
| Age | 57 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | 3000 Steeles Avenue East, Markham, ON, Canada, L3R 4T9 |
| Phone | 905 470 4000 |
| Web | https://www.extendicare.com |
Extendicare Management Efficiency
The company has return on total asset (ROA) of 0.0998 % which means that it generated a profit of $0.0998 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7086 %, meaning that it generated $0.7086 on every $100 dollars invested by stockholders. Extendicare's management efficiency ratios could be used to measure how well Extendicare manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Extendicare's Return On Tangible Assets are very stable compared to the past year. As of the 24th of March 2025, Return On Assets is likely to grow to 0.11, while Return On Capital Employed is likely to drop 0.12. At this time, Extendicare's Debt To Assets are very stable compared to the past year. As of the 24th of March 2025, Fixed Asset Turnover is likely to grow to 5.21, while Non Currrent Assets Other are likely to drop about 28 M.Similar Executives
| Found 12 records | DIRECTOR Age | ||
| Tony Hupman | Chemtrade Logistics Income | N/A | |
| Edward Warkentin | Exchange Income | 69 | |
| Stephen Sender | Sienna Senior Living | 60 | |
| Donald Streuber | Exchange Income | 61 | |
| Janet Graham | Sienna Senior Living | 64 | |
| Serena Kraayeveld | Exchange Income | 67 | |
| Polly Craik | Exchange Income | 57 | |
| Paula Coleman | Sienna Senior Living | 66 | |
| Gary Buckley | Exchange Income | 58 | |
| Jack MacDonald | Sienna Senior Living | 73 | |
| Melissa Sonberg | Exchange Income | 58 | |
| Brad Bennett | Exchange Income | 61 | |
Management Performance
| Return On Equity | 0.71 | ||||
| Return On Asset | 0.0998 |
Extendicare Leadership Team
Elected by the shareholders, the Extendicare's board of directors comprises two types of representatives: Extendicare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Extendicare. The board's role is to monitor Extendicare's management team and ensure that shareholders' interests are well served. Extendicare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Extendicare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jillian CPA, Vice Relations | ||
| Ali Mir, Vice President - ParaMed Operations | ||
| Samir Manji, Independent Director | ||
| Brent Houlden, Independent Director | ||
| Kathryn Bradley, Vice Development | ||
| MBA MD, President CEO | ||
| Amie Vahrmeyer, Vice ON | ||
| Jillian Fountain, Vice President - Investor Relations | ||
| Liselie Sarauer, Chief Human Resource Officer, Senior Vice President | ||
| Katie LeMoyne, Senior Officer | ||
| Bruce Wienberg, VP Care | ||
| Elaine Everson, Vice President - Corporate Development | ||
| Danielle Parr, Vice Affairs | ||
| Sandra Hanington, Independent Director | ||
| Wendy Gilmour, Senior Operations | ||
| Lisa Pearson, VP Affairs | ||
| Alan Hibben, Independent Director | ||
| David Bacon, Chief Financial Officer, Senior Vice President | ||
| Matthew Morgan, Chief Officer | ||
| Leslie Sarauer, VP Officer | ||
| Donna Kingelin, Independent Director | ||
| Joe Belinsky, VP Officer | ||
| Alan Torrie, Independent Chairman of the Board | ||
| Michael Guerriere, President, Chief Executive Officer, Director | ||
| Norma Beauchamp, Independent Director | ||
| David CPA, Executive CFO | ||
| John Toffoletto, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| Steve Paraskevopoulos, Senior CTO | ||
| Aladin Mawani, Independent Director |
Extendicare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Extendicare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.71 | ||||
| Return On Asset | 0.0998 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 83.47 M | ||||
| Shares Owned By Insiders | 13.87 % | ||||
| Shares Owned By Institutions | 20.50 % | ||||
| Number Of Shares Shorted | 1.05 M | ||||
| Price To Earning | 26.74 X |
Pair Trading with Extendicare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Extendicare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Extendicare will appreciate offsetting losses from the drop in the long position's value.Moving against Extendicare Stock
| 0.95 | TSLA | Tesla Inc CDR | PairCorr |
| 0.88 | MSFT | Microsoft Corp CDR | PairCorr |
| 0.86 | GOOG | Alphabet CDR | PairCorr |
| 0.84 | AVGO | Broadcom | PairCorr |
| 0.81 | AMZN | Amazon CDR | PairCorr |
The ability to find closely correlated positions to Extendicare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Extendicare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Extendicare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Extendicare to buy it.
The correlation of Extendicare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Extendicare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Extendicare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Extendicare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Extendicare Stock
Extendicare financial ratios help investors to determine whether Extendicare Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Extendicare with respect to the benefits of owning Extendicare security.